Trans-capsular p38 MAP Kinase Inhibitor Delivery for Joint Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for degenerative joint disease (DJD) and facet joint disorders are inadequate, particularly in addressing pain and joint damage, with existing methods providing temporary relief and potential complications such as hypermobility or contraindications for artificial joints.
Innovation Solution
The use of localized drug therapy involving p38 MAP kinase inhibitors administered trans-capsularly to block pro-inflammatory cytokines and enzymes, combined with additional therapeutic agents like mesenchymal stem cells and anti-oxidants, to reduce inflammation and degeneration in the joint.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If facet blocks with anesthetic and cortisone are used for temporary relief of pain, then pain control is achieved, but the relief is only temporary and does not address underlying degeneration
Solution Approach 1:
The patent changes the pharmacological parameters by using p38 MAP kinase inhibitors with different mechanisms of action compared to traditional anesthetics and cortisone. These inhibitors target specific molecular pathways (blocking pro-inflammatory cytokines and enzymes) to provide sustained treatment effect rather than temporary symptom masking, thereby extending the duration of action and improving reliability of pain management.
Solution Approach 2:
The patent replaces the mechanical/symptomatic approach of facet blocks (which temporarily numb pain receptors) with a molecular/biochemical approach using p38 MAP kinase inhibitors that address the underlying inflammatory and degenerative processes. This substitution transitions from masking symptoms to treating the root cause, providing more durable therapeutic effects.
2Reliability
If facetectomy is performed to provide relief, then pain relief is achieved, but spinal column stiffness significantly decreases causing hypermobility
Solution Approach 1:
The patent applies local quality by delivering p38 MAP kinase inhibitors directly into the facet joint capsule via trans-capsular injection. This localized delivery concentrates the therapeutic effect at the site of pathology (inflamed joint capsule and surrounding tissues) while preserving the structural integrity and mechanical stability of the spinal column, thereby achieving pain relief without compromising spinal stiffness.
Solution Approach 2:
The patent extracts or removes the harmful inflammatory mediators and pro-inflammatory molecules from the joint environment by using p38 MAP kinase inhibitors that block their production and activity. This selective removal of pathological elements (cytokines, enzymes) preserves the normal structural components of the facet joint and spinal column, maintaining stability while eliminating pain sources.
3Manufacturing precision
If trans-capsular administration of p38 MAP kinase inhibitors is used, then targeted treatment of pro-inflammatory molecules is achieved, but the complexity of the treatment procedure increases
Solution Approach 1:
The patent uses the joint capsule itself as an intermediary structure for drug delivery. By injecting p38 MAP kinase inhibitors trans-capsularly (through the capsule into the joint space), the capsule serves as a natural delivery vehicle that concentrates the medication at the target site. This approach achieves high targeting precision without requiring complex targeted delivery systems or multiple injection sites, thereby limiting the increase in procedural complexity.
Data Source
AI summary
The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.